北京时间2024年11月11日,生物技术公司Arcturus Therapeutics Holdings Inc.(ARCT)股价盘中大涨5.13%,引发市场关注。
公司最新财报显示,第三季度营收3882万美元,环比增长38%;净利润亏损690万美元,亏损有所扩大。尽管亏损加大,但分析人士认为,公司在罕见疾病领域的产品线前景广阔,有望带动长期收入增长。
另一利好因素是,目前参与评级的11家机构均给予买入评级,看好公司长期投资价值。一些分析指出,公司专注RNA药物研发,在肝脏和呼吸系统等疾病领域拥有多个在研产品,未来发展值得期待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.